Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Omeros announces financial results for second quarter of 2013

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

12 Aug 2013

Study provides efficient strategy for prevention of rotavirus infection

For children and immune compromised adults in developing countries, diarrheal disease induced by rotavirus can be life threatening. Current rotaviral vaccines are highly effective in the Western world, but are not as effective in developing countries.

9 Aug 2013

Study: Immune-regulating molecules can trigger lymphomas

A small group of immune-regulating molecules, when overproduced even moderately, can trigger the blood cancers known as lymphomas, according to a new study led by scientists from The Scripps Research Institute (TSRI).

9 Aug 2013

New reagent kits for intracellular staining from Beckman Coulter Life Sciences

PerFix-Expose1 and PerFix-nc1, innovative new reagent kits for intracellular staining from Beckman Coulter Life Sciences, minimize sample manipulation for a streamlined workflow that delivers high quality results. Developed for use on Beckman Coulter’s Gallios1 and Navios2 series flow cytometers and compatible with all Beckman Coulter Life Sciences’ fluorochromes, the kits enable a clear focus on the cytoplasmic and nuclear compartments of the cell.

8 Aug 2013

NCI renews UCLA prostate SPORE grant

UCLA's Jonsson Comprehensive Cancer Center and the department of urology at the David Geffen School of Medicine at UCLA have been notified that their standing as a National Cancer Institute Specialized Program of Research Excellence site in prostate cancer has been renewed for another five years.

8 Aug 2013

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial.

8 Aug 2013

Updated United States Public Health Service guidelines for management of occupational exposure to HIV

New guidelines from the United States Public Health Service update the recommendations for the management of healthcare personnel with occupational exposure to HIV and use of postexposure prophylaxis.

7 Aug 2013

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

Bayer Collaboration Could Net $540M+ For Compugen

...

6 Aug 2013

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Compugen Ltd. announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators.

5 Aug 2013

New study paves way for novel approaches to protect people from infections

A new study published by University of Utah researchers is paving the way for novel approaches related to how people are immunized to protect them from diseases.

3 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

New finding suggests potential to improve safety, performance of reprogrammed cells

The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.

2 Aug 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

Deletion of a protein improves ability to fight bacteria in mice with CGD

Deletion of a protein in white blood cells improves their ability to fight the bacteria staphylococcus aureus and possibly other infections in mice with chronic granulomatous disease (CGD), according to a National Institutes of Health study. CGD, a genetic disorder also found in people, is marked by recurrent, life-threatening infections. The study's findings appear online in The Journal of Clinical Investigation.

2 Aug 2013

Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.

2 Aug 2013